유전체 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global genomic biomarkers market size is expected to reach USD 14.47 Billion in 2034 from USD 6.08 Billion in 2025, growing at a CAGR of 10.11% during 2026-2034.This market is growing as genomic biomarkers become increasingly important in disease diagnosis, treatment selection, and the assessment of therapeutic response. Genomic biomarkers include genetic variations, mutations, gene expression patterns, and other molecular characteristics that provide information about disease biology. Their use is particularly significant in oncology, where biomarker testing can help identify patients who may benefit from targeted therapies. Increasing interest in precision medicine, improvements in molecular diagnostic technologies, and the expansion of biomarker-driven clinical trials are supporting demand. Pharmaceutical developers are also using genomic biomarkers to refine clinical research and evaluate potential treatment effectiveness.

Market growth is driven by advances in next-generation sequencing, declining costs of molecular analysis, and increasing investment in drug development. Diagnostic laboratories are expanding their capabilities to identify clinically relevant genetic alterations, while pharmaceutical companies are incorporating biomarker strategies into clinical trials. Regulatory recognition of certain biomarker-guided treatments and the development of companion diagnostics are further supporting market expansion. Improved bioinformatics platforms are helping researchers analyze large genomic datasets and identify associations between molecular characteristics and treatment outcomes. In addition, collaborations between biotechnology companies, academic institutions, and healthcare providers are encouraging the discovery and validation of new biomarkers.

The future prospects of this market will depend on continued biomarker discovery, stronger clinical validation, and broader integration into routine healthcare. Advances in liquid biopsy, multi-omics analysis, and artificial intelligence may help researchers identify additional biomarkers and monitor changes in disease biology. Biomarker-guided treatment selection could expand across oncology and other therapeutic areas as supporting evidence develops. However, challenges involving data interpretation, test standardization, reimbursement, and the clinical significance of certain genomic findings will remain important. Continued investment in validated testing methods and the integration of biomarker results into clinical decision-making could strengthen the role of genomic biomarkers in personalized healthcare.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Renal Disorders
• Auto-Immune & Inflammatory Diseases
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Others

By Technology Platform

• Next-Generation Sequencing
• PCR
• Microarray
• Others

By Biomarker Type

• Predictive Biomarkers
• Prognostic Biomarkers

COMPANIES PROFILED

• Foundation Medicine/Roche, Guardant Health, Illumina, Thermo Fisher Scientific, QIAGEN, Natera, Tempus AI, Exact Sciences/Abbott, NeoGenomics, Caris Life Sciences, Personalis, Fulgent Genetics, Invitae, Labcorp, Quest Diagnostics, Veracyte, Burning Rock Biotech, BGI Genomics, GeneCentric Therapeutics, Bio-Rad Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENOMIC BIOMARKERS MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Cardiovascular Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Renal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Auto-Immune & Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENOMIC BIOMARKERS MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENOMIC BIOMARKERS MARKET: BY TECHNOLOGY PLATFORM 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology Platform
• 6.2. Next-Generation Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Microarray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENOMIC BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Biomarker Type
• 7.2. Predictive Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Prognostic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENOMIC BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By End User
  • 8.2.3 By Technology Platform
  • 8.2.4 By Biomarker Type
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By End User
  • 8.3.3 By Technology Platform
  • 8.3.4 By Biomarker Type
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By End User
  • 8.4.3 By Technology Platform
  • 8.4.4 By Biomarker Type
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By End User
  • 8.5.3 By Technology Platform
  • 8.5.4 By Biomarker Type
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By End User
  • 8.6.3 By Technology Platform
  • 8.6.4 By Biomarker Type
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENOMIC BIOMARKERS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Foundation Medicine/Roche
  • 10.2.2 Guardant Health
  • 10.2.3 Illumina
  • 10.2.4 Thermo Fisher Scientific
  • 10.2.5 QIAGEN
  • 10.2.6 Natera
  • 10.2.7 Tempus AI
  • 10.2.8 Exact Sciences/Abbott
  • 10.2.9 NeoGenomics
  • 10.2.10 Caris Life Sciences
  • 10.2.11 Personalis
  • 10.2.12 Fulgent Genetics
  • 10.2.13 Invitae
  • 10.2.14 Labcorp
  • 10.2.15 Quest Diagnostics
  • 10.2.16 Veracyte
  • 10.2.17 Burning Rock Biotech
  • 10.2.18 BGI Genomics
  • 10.2.19 GeneCentric Therapeutics
  • 10.2.20 Bio-Rad Laboratories